vs
KILROY REALTY CORP（KRC）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
KILROY REALTY CORP的季度营收约是Ultragenyx Pharmaceutical Inc.的1.3倍（$272.2M vs $207.3M），KILROY REALTY CORP净利率更高（6.3% vs -62.0%，领先68.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -5.0%），KILROY REALTY CORP自由现金流更多（$450.3M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -1.2%）
基尔罗伊房地产公司是美国领先的房地产投资信托企业，主要在洛杉矶、旧金山、西雅图、圣地亚哥等美国西海岸核心市场开发、持有及运营优质办公、生命科学及混合用途物业，面向科技、生命科学、文创等领域租户，主打可持续的现代化办公空间。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
KRC vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $272.2M | $207.3M |
| 净利润 | $17.1M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 6.3% | -62.0% |
| 营收同比 | -5.0% | 25.9% |
| 净利润同比 | -73.7% | 3.5% |
| 每股收益（稀释后） | $0.11 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $272.2M | $207.3M | ||
| Q3 25 | $279.7M | $159.9M | ||
| Q2 25 | $289.9M | $166.5M | ||
| Q1 25 | $270.8M | $139.3M | ||
| Q4 24 | $286.4M | $164.6M | ||
| Q3 24 | $289.9M | $139.5M | ||
| Q2 24 | $280.7M | $147.0M | ||
| Q1 24 | $278.6M | $108.8M |
| Q4 25 | $17.1M | $-128.6M | ||
| Q3 25 | $162.3M | $-180.4M | ||
| Q2 25 | $79.6M | $-115.0M | ||
| Q1 25 | $43.7M | $-151.1M | ||
| Q4 24 | $65.0M | $-133.2M | ||
| Q3 24 | $57.7M | $-133.5M | ||
| Q2 24 | $54.5M | $-131.6M | ||
| Q1 24 | $55.7M | $-170.7M |
| Q4 25 | — | -54.7% | ||
| Q3 25 | — | -106.9% | ||
| Q2 25 | — | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | — | -94.6% | ||
| Q2 24 | — | -79.1% | ||
| Q1 24 | — | -151.9% |
| Q4 25 | 6.3% | -62.0% | ||
| Q3 25 | 58.0% | -112.8% | ||
| Q2 25 | 27.4% | -69.0% | ||
| Q1 25 | 16.1% | -108.5% | ||
| Q4 24 | 22.7% | -80.9% | ||
| Q3 24 | 19.9% | -95.7% | ||
| Q2 24 | 19.4% | -89.5% | ||
| Q1 24 | 20.0% | -156.8% |
| Q4 25 | $0.11 | $-1.28 | ||
| Q3 25 | $1.31 | $-1.81 | ||
| Q2 25 | $0.57 | $-1.17 | ||
| Q1 25 | $0.33 | $-1.57 | ||
| Q4 24 | $0.50 | $-1.34 | ||
| Q3 24 | $0.44 | $-1.40 | ||
| Q2 24 | $0.41 | $-1.52 | ||
| Q1 24 | $0.42 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $179.3M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.4B | $-80.0M |
| 总资产 | $10.9B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $179.3M | $421.0M | ||
| Q3 25 | $372.4M | $202.5M | ||
| Q2 25 | $193.1M | $176.3M | ||
| Q1 25 | $146.7M | $127.1M | ||
| Q4 24 | $165.7M | $174.0M | ||
| Q3 24 | $625.4M | $150.6M | ||
| Q2 24 | $835.9M | $480.7M | ||
| Q1 24 | $855.0M | $112.3M |
| Q4 25 | $5.4B | $-80.0M | ||
| Q3 25 | $5.5B | $9.2M | ||
| Q2 25 | $5.4B | $151.3M | ||
| Q1 25 | $5.4B | $144.2M | ||
| Q4 24 | $5.4B | $255.0M | ||
| Q3 24 | $5.4B | $346.8M | ||
| Q2 24 | $5.4B | $432.4M | ||
| Q1 24 | $5.4B | $140.3M |
| Q4 25 | $10.9B | $1.5B | ||
| Q3 25 | $11.0B | $1.2B | ||
| Q2 25 | $10.9B | $1.3B | ||
| Q1 25 | $10.9B | $1.3B | ||
| Q4 24 | $10.9B | $1.5B | ||
| Q3 24 | $11.4B | $1.5B | ||
| Q2 24 | $11.5B | $1.6B | ||
| Q1 24 | $11.6B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $566.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $450.3M | $-100.8M |
| 自由现金流率自由现金流/营收 | 165.4% | -48.6% |
| 资本支出强度资本支出/营收 | 42.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 33.10× | — |
| 过去12个月自由现金流最近4个季度 | $833.0M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $566.3M | $-99.8M | ||
| Q3 25 | $176.6M | $-91.4M | ||
| Q2 25 | $143.7M | $-108.3M | ||
| Q1 25 | $136.9M | $-166.5M | ||
| Q4 24 | $541.1M | $-79.3M | ||
| Q3 24 | $176.3M | $-67.0M | ||
| Q2 24 | $88.7M | $-77.0M | ||
| Q1 24 | $167.9M | $-190.7M |
| Q4 25 | $450.3M | $-100.8M | ||
| Q3 25 | $148.7M | $-92.7M | ||
| Q2 25 | $118.4M | $-110.7M | ||
| Q1 25 | $115.6M | $-167.8M | ||
| Q4 24 | $440.8M | $-79.5M | ||
| Q3 24 | $147.2M | $-68.6M | ||
| Q2 24 | $69.5M | $-79.0M | ||
| Q1 24 | $151.9M | $-193.9M |
| Q4 25 | 165.4% | -48.6% | ||
| Q3 25 | 53.1% | -58.0% | ||
| Q2 25 | 40.9% | -66.5% | ||
| Q1 25 | 42.7% | -120.5% | ||
| Q4 24 | 153.9% | -48.3% | ||
| Q3 24 | 50.8% | -49.2% | ||
| Q2 24 | 24.7% | -53.7% | ||
| Q1 24 | 54.5% | -178.2% |
| Q4 25 | 42.6% | 0.5% | ||
| Q3 25 | 10.0% | 0.8% | ||
| Q2 25 | 8.7% | 1.5% | ||
| Q1 25 | 7.9% | 1.0% | ||
| Q4 24 | 35.0% | 0.1% | ||
| Q3 24 | 10.1% | 1.2% | ||
| Q2 24 | 6.8% | 1.4% | ||
| Q1 24 | 5.7% | 3.0% |
| Q4 25 | 33.10× | — | ||
| Q3 25 | 1.09× | — | ||
| Q2 25 | 1.81× | — | ||
| Q1 25 | 3.13× | — | ||
| Q4 24 | 8.32× | — | ||
| Q3 24 | 3.06× | — | ||
| Q2 24 | 1.63× | — | ||
| Q1 24 | 3.01× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KRC
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
